N-[(2R)-2,3-Dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
-
![N-[(2R)-2,3-Dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide structure](https://file.echemi.com/fileManage/upload/canonicalSmiles/20220811/73d857907ed04480b4256a86505678c7.png "N-[(2R)-2,3-Dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide")
N-[(2R)-2,3-Dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
structure -
-
CAS No:
391210-10-9
-
Formula:
C16H14F3IN2O4
-
Chemical Name:
N-[(2R)-2,3-Dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
-
Synonyms:
Benzamide,N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-;N-[(2R)-2,3-Dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide;N-[((R)-2,3-Dihydroxypropyl)oxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide;PD 0325901;PD 325901;PD 901;N-[(2R)-2,3-Dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide;PD 03525901;Mirdametinib;870474-62-7
- Categories:
-
CAS No:
Description
PD0325901 is a selective and cell permeable MEK inhibitor with an IC50 of 0.33 nM.
PD 0325901 is a hydroxamic acid ester that is benzhydroxamic acid (N-hydroxybenzamide) in which the hydroxamic acid group has been converted to the corresponding 2,3-dihydroxypropyl ester and in which the benzene ring has been substituted at position 2 by a (2-fluoro-4-iodophenyl)amino group and at positions 3 and 4 by fluorines (the R enantiomer). It has a role as an EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor and an antineoplastic agent. It is a hydroxamic acid ester, a secondary amino compound, a member of monofluorobenzenes, an organoiodine compound, a member of propane-1,2-diols and a difluorobenzene.|PD-0325901 has been used in trials studying the treatment and basic science of Melanoma, Solid Tumour, Solid Tumors, Advanced Cancer, and Breast Neoplasms, among others.|Mirdametinib is an orally bioavailable, synthetic organic molecule targeting mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. Upon administration, mirdametinib selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors.
N-[(2R)-2,3-Dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide Basic Attributes
482.191
482.19
1592732-453-0
86K0J5AK6M
DTXSID0044024
C52195
29242990
Characteristics
90.82000
2.93060
white to off-white
1.8±0.1 g/cm3
112-114°C
1.645
DMSO: soluble20mg/mL, clear
Store at -20°C
Safety Information
Ⅲ
IRRITANT
UN 2811 6.1 / PGIII
3
25-48-50
22-36/37/39-61
T,N
P273-P301 + P310 + P330-P391-P501
H301-H373-H410
|Danger|H301 (97.5%): Toxic if swallowed [Danger Acute toxicity, oral]|P260, P264, P270, P273, P301+P310, P314, P321, P330, P391, P405, and P501|Aggregated GHS information provided by 40 companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
N-[(2R)-2,3-Dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide Use and Manufacturing
The mitogenic extracellular kinase 1/2 (MEK1/2) inhibitor
Computed Properties
Molecular Weight:482.19
XLogP3:3
Hydrogen Bond Donor Count:4
Hydrogen Bond Acceptor Count:8
Rotatable Bond Count:7
Exact Mass:481.99504
Monoisotopic Mass:481.99504
Topological Polar Surface Area:90.8
Heavy Atom Count:26
Complexity:465
Defined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes
Recommended Suppliers of N-[(2R)-2,3-Dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
-
![China]()
CN
5 YRS
Business licensedTrader Supplier of Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals,Biochemicals,Pharmaceuticals,Screening Compounds,Food Additives -
![China]()
CN
6 YRS
Business licensed Certified factoryManufactory Supplier of Chloranil,Ascomycin,Gemcitabine,Levamlodipine,Isoflurane,1-(4-Pyridyl)acetone,Peramivir,SiO2,Aluminum oxide,Posaconazole Main Ring,Rapamycin,Clemastine fumarate,Tacrolimus,SiO,Milrinone,Benzyl alcohol,Isavuconazole intermediate,Clofarabine,Prasugrel,Daptomycin,hydroxyapatite,1,Atracurium oxalate,Atazanavir sulfate,Decitabine,Zirconium dioxide,5-Pentanediol diacrylate,Darunavir,Vorapaxar intermediate,Meloxicam,Carfilzomib,Miglitol,Isavuconazole
Latest News on N-[(2R)-2,3-Dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
- BMS Over $900 Million to Help Develop Potential 'Best-in-class' SHP2 Inhibitors
- AbbVie's blockbuster product for atopic dermatitis, Upadacitinib, has been approved for marketing in the EU and Japan
- Designing peptide inhibitors for possible COVID-19 treatments
- Chinese scientists discover the inhibitors of SARS-CoV-2
Learn More Other Chemicals
-
Dabrafenib
1195765-45-7
-
BOC-VAL-VAL-OH
69209-73-0
-
BMS 303141
943962-47-8
-
(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanamide Formula
60117-17-1
-
(2S)-2-acetamido-6-amino-N-[(2S)-2-amino-3-methylbutanoyl]-N-propylhexanamide Formula
57899-96-4
-
1-(6-methoxy-1,3-benzothiazol-2-yl)-3-phenylurea Formula
26130-02-9
-
L-Tyrosyl-L-phenylalanine Structure
17355-11-2
-
C-REACTIVE PROTEIN FRAGMENT 77-82 Structure
130349-01-8
-
What is Sildenafil
139755-83-2
-
What is Dacomitinib
1110813-31-4
N-[(2R)-2,3-Dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
SDSRequest for Quotation